Abstract:Background: Gastric cancer is a highly heterogeneous disease, presenting a major obstacle to personalized treatment. Effective markers of the immune checkpoint blockade response are needed for precise patient classification. We, therefore, divided patients with gastric cancer according to collagen gene expression to indicate their prognosis and treatment response. Methods: We collected data for 1250 patients with gastric cancer from four cohorts. For the TCGA-STAD cohort, we used consensus clustering to stratify patients based on expression levels of 44 collagen genes and compared the prognosis and clinical characteristics between collagen subtypes. We then identified distinct transcriptomic and genetic alteration signatures for the subtypes. We analyzed the associations of collagen subtypes with the responses to chemotherapy, immunotherapy, and targeted therapy. We also established a platform-independent collagen-subtype predictor. We verified the findings in three validation cohorts (GSE84433, GSE62254, and GSE15459) and compared the collagen subtyping method with other molecular subtyping methods. Results: We identified two subtypes of gastric adenocarcinoma: a high-expression collagen subtype (CS-H) and a low-expression collagen subtype (CS-L). Collagen subtype was an independent prognostic factor, with better overall survival in the CS-L subgroup. The inflammatory response, angiogenesis, and phosphoinositide 3-kinase (PI3K)/Akt pathways were transcriptionally active in the CS-H subtype, while DNA repair activity was significantly greater in the CS-L subtype. PIK3CA was frequently amplified in the CS-H subtype, while PIK3C2A, PIK3C2G, and PIK3R1 were frequently deleted in the CS-L subtype. CS-H subtype tumors were more sensitive to fluorouracil, while CS-L subtype tumors were more sensitive to immune checkpoint blockade. CS-L subtype was predicted to be more sensitive to HER2-targeted drugs, and CS-H subtype was predicted to be more sensitive to vascular endothelial growth factor and PI3K pathway-targeting drugs. Collagen subtyping also has the potential to be combined with existing molecular subtyping methods for better patient classification. Conclusions: We classified gastric cancers into two subtypes based on collagen gene expression and validated these subtypes in three validation cohorts. The collagen subgroups differed in terms of prognosis, clinical characteristics, transcriptome, and genetic alterations. The subtypes were closely related to patient responses to chemotherapy, immunotherapy, and targeted therapy.

Prognostic effect of immunohistochemically determined molecular subtypes in gastric cancer

Prognostic Effects of Clinical Parameters, Genetic Abnormalities, and Subtypes in Primary Gastric Diffuse Large B-cell Lymphoma: a Cohort Analysis of 146 Patients

Gastric cancer molecular classification based on immunohistochemistry and in‐situ hybridisation and mortality

Prediction of Two Molecular Subtypes of Gastric Cancer Based on Immune Signature

Protein Expression-Based Classification Of Gastric Cancer By Immunohistochemistry Of Tissue Microarray

Molecular Classification of Esophagogastric Junction Carcinoma Correlated with Prognosis

Molecular classification reveals the diverse genetic features and prognosis of gastric cancer: a multi-omics consensus ensemble clustering

Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering

Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma

The Tumour Immune Microenvironment Drives Survival Outcomes and Therapeutic Response in an Integrated Molecular Analysis of Gastric Adenocarcinoma

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Molecular Typing of Gastric Cancer Based on Invasion-Related Genes and Prognosis-Related Features.

Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Diverse ‘just-right’ levels of chromosomal instability and their clinical implications in neoadjuvant treated gastric cancer

Immunohistochemical classification of gastric cancer based on new molecular biomarkers: a potential predictor of survival

Classification of Gastric Cancer by EBV Status Combined with Molecular Profiling Predicts Patient Prognosis.

Microsatellite Instability and Epstein-Barr Virus Combined with PD-L1 Could Serve As a Potential Strategy for Predicting the Prognosis and Efficacy of Postoperative Chemotherapy in Gastric Cancer.

Identifying gastric cancer molecular subtypes by integrating DNA-based hierarchical classification strategy and clinical stratification

Abstract 5142: Proteome-wide Analysis Identifies Three Subgroups of Diffuse-Type Gastric Cancer

Identification of collagen subtypes of gastric cancer for distinguishing patient prognosis and therapeutic response